Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- More Pharmacies Turning to Medical System Network’s Price Negotiation Service after Distribution Guidelines Introduced
March 1, 2019
- JCR’s Hunter Syndrome Drug Earns Orphan Status in Europe
March 1, 2019
- Mitsubishi Tanabe, Servier Tie Up on Tenelia Promotion in China
March 1, 2019
- EMA Accepts Astellas’ AML Drug Xospata for Review, Approval Could Come This Summer
March 1, 2019
- Takeda, Aflac, 6 Other Firms to Develop Insurance with Healthy Living Rewards in 1st Shonan Initiative
February 28, 2019
- Pfizer Transferring MA/Distribution Rights for 3 Off-Patent Brands to Teikoku Seiyaku
February 28, 2019
- Ono Files Parkinson’s Drug Opicapone in Japan
February 28, 2019
- Eisai to Fund Japan NGO for Prevention of Infectious Diseases in Sudan
February 28, 2019
- Ono’s Braftovi/Mektovi Combo, Demser Now Available; Takeda’s Fibroid Drug to Hit Shelves on March 1
February 27, 2019
- BMS Seeks Japan Approval for New Empliciti Triplet
February 27, 2019
- Lonsurf Gets Gastric Cancer Nod in US
February 27, 2019
- AbbVie Files Japan NDA for Oral JAK Inhibitor
February 27, 2019
- Nihon Generic Taking Pass on June Listing of Symbicort Copies; 2 Partners Mum
February 27, 2019
- Kowa’s Biz Realignment Reflects Globalization, Workstyle Reform, but No Job Cull Planned: President
February 27, 2019
- Roche Diagnostics Files PD-L1 Expression Assay for Use in Breast Cancer in Japan
February 27, 2019
- FunPep Gets Green Light for Clinical Study in Australia of Antibody-Inducing Peptide for Psoriasis
February 27, 2019
- Shionogi Specialty Squad Providing Deep Info on Mulpleta/Pirespa, Aims for Higher Sales with Fewer Calls
February 26, 2019
- Epclusa Hits Japan Market, 1st Drug for Hep C with Decompensated Cirrhosis
February 26, 2019
- Kentaro Murakawa Named as New President for Daiichi Sankyo Espha
February 26, 2019
- Takeda Japan Chief Says Shire Buy Only Bolsters Home Operations with No Overlaps, Nixes Job Cuts
February 25, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…